Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Bakhos A. Tannous, Ph.D.


This page shows the publications co-authored by Bakhos Tannous and Jian Teng.
Connection Strength

  1. The natural compound obtusaquinone targets pediatric high-grade gliomas through ROS-mediated ER stress. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa106.
    View in: PubMed
    Score: 0.915
  2. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Neuro Oncol. 2018 04 09; 20(5):642-654.
    View in: PubMed
    Score: 0.776
  3. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Neuro Oncol. 2017 06 01; 19(6):820-832.
    View in: PubMed
    Score: 0.731
  4. Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy. Stem Cells. 2014 Aug; 32(8):2021-32.
    View in: PubMed
    Score: 0.601
  5. Secreted blood reporters: insights and applications. Biotechnol Adv. 2011 Nov-Dec; 29(6):997-1003.
    View in: PubMed
    Score: 0.492
  6. Olfactory Ensheathing Cells: A Trojan Horse for Glioma Gene Therapy. J Natl Cancer Inst. 2019 03 01; 111(3):283-291.
    View in: PubMed
    Score: 0.206
  7. Triple bioluminescence imaging for in vivo monitoring of cellular processes. Mol Ther Nucleic Acids. 2013 Jun 18; 2:e99.
    View in: PubMed
    Score: 0.139
  8. Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: first steps toward the clinic. EMBO Mol Med. 2016 Mar 01; 8(3):268-87.
    View in: PubMed
    Score: 0.042
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.